

# ESMO Preceptorship on Metastatic Bladder and Kidney Cancer

## PROGRAMME

**ESMO  
PRECEPTORSHIP**

**ZURICH SWITZERLAND  
3-4 APRIL 2025**

**Co-Chairs**

Laurence Albiges, France  
Viktor Grünwald, Germany

# ESMO PRECEPTORSHIP PROGRAMME METASTATIC BLADDER AND KIDNEY CANCER

Multidisciplinary management, standards of care,  
therapeutic targets and future perspectives

Zurich, Switzerland  
3-4 April 2025

---

## CO-CHAIRS

Laurence Albiges, France  
Viktor Grünwald, Germany

## SPEAKERS

Axel Bex, Netherlands  
Guillermo de Velasco, Spain  
Patrizia Giannatempo, Italy  
Yohann Loriot, France  
Morgan Roupret, France  
Cristina Suárez, Spain  
Bernadett Szabados, United Kingdom  
Ursula Vogl, Switzerland  
Stefanie Zschäbitz, Germany

---

## LEARNING OBJECTIVES

- To learn about fundamentals of molecular pathology and diagnosis as contributing factors to heterogeneity in bladder and kidney cancer
- To understand essentials in the assessment and multidisciplinary treatment of bladder and kidney cancer
- To learn about advances in treatment and novel targets in bladder and kidney cancer

---

## ACCREDITATION

The programme of this event has been accredited with **9 ESMO-MORA category 1 points**.

Recertification is necessary for medical oncologists to remain professionally certified by ESMO. Recertification guarantees that a certified medical oncologist has continued to update his/her knowledge and continues to possess the necessary skills and standards for the practice of medical oncology. For further details please refer to [esmo.org](http://esmo.org).

---

## ACKNOWLEDGEMENTS

This event is supported by an unrestricted educational grant from



---

## ORGANISATION AND CONTACTS

ESMO Head Office  
Education Department  
Via Ginevra 4  
6900 Lugano, Switzerland  
Email: [courses@esmo.org](mailto:courses@esmo.org)  
[www.esmo.org](http://www.esmo.org)



## Thursday, 3 April 2025

<b>09:00-09:15</b> 15'	<b>Opening and welcome</b>	
15'	Welcome from ESMO - Objectives and scientific introduction	Laurence Albiges, FR Viktor Grünwald, DE
<b>09:15-10:45</b> 90'	<b>SESSION 1</b> <b>Bladder Cancer – Part I</b>	<b>Chairs:</b> <b>Yohann Lorient, FR</b> <b>Ursula Vogl, CH</b>
15'	New treatments and approaches to NMIBC: What the oncologist needs to know	Morgan Roupret, FR
20'	Neoadjuvant treatments for MIBC	Bernadett Szabados, UK
15'	Summary of adjuvant therapies for MIBC	Patrizia Giannatempo, IT
10'	Conservative approach in MIBC	Bernadett Szabados, UK
15'	Biomarkers in perioperative bladder cancer	Yohann Lorient, FR
15'	Q&A	All
<b>10:45-11:15</b>	<b>Coffee break</b>	
<b>11:15-12:45</b> 90'	<b>SESSION 2</b> <b>Bladder Cancer – Part II</b>	<b>Chairs:</b> <b>Patrizia Giannatempo, IT</b> <b>Viktor Grünwald, DE</b>
15'	First line treatment in advanced bladder cancer	Stefanie Zschäbitz, DE
15'	Second line and beyond in advanced bladder cancer	Yohann Lorient, FR
15'	Approaches to upper tract UC	Morgan Roupret, FR
15'	Q&A	All
30'	Participants clinical case discussion (3x10')	Faculty
<b>12:45-13:45</b>	<b>Lunch</b>	
<b>13:45-15:10</b> 85'	<b>SESSION 3</b> <b>Renal Cancer – Part I</b>	<b>Chairs:</b> <b>Laurence Albiges, FR</b> <b>Viktor Grünwald, DE</b>
10'	Is there a role for nephrectomy in advanced disease?	Axel Bex, NL
10'	Is there a role for neoadjuvant treatment in RCC?	Axel Bex, NL
10'	Oligometastatic disease management	Guillermo de Velasco, ES
15'	Q&A	All
40'	Participants clinical case discussion (4x10')	Faculty
<b>15:10-15:40</b>	<b>Coffee Break</b>	

<b>15:40-17:15</b> <b>95'</b>	<b>SESSION 4</b> <b>Debate around adjuvant therapy for RCC</b>	<b>Chairs:</b> <b>Guillermo de Velasco, ES</b> <b>Stefanie Zschäbitz, DE</b>
15'	Summary of adjuvant therapies for RCC	Cristina Suárez, ES
10'	Adjuvant treatment selection for localised RCC	Guillermo de Velasco, ES
10'	Surgeon's point of view: Assessing the risk of relapse	Axel Bex, NL
15'	Treatment after progression on adjuvant therapy in renal carcinoma	Ursula Vogl, CH
15'	Q&A	All
30'	Participants clinical case discussion (3x10')	Faculty
<b>19:30</b>	<b>Dinner</b>	

## Friday, 4 April 2025

<b>09:00-10:20</b> <b>80'</b>	<b>SESSION 5</b> <b>Renal Cancer – Part II</b>	<b>Chairs:</b> <b>Guillermo de Velasco, ES</b> <b>Ursula Vogl, CH</b>
20'	Debate: Immune combinations or VEGF/PD1 inhibition as first line therapy for advanced clear cell RCC <ul style="list-style-type: none"> <li>- Immune combinations</li> <li>- VEGF/PD1 inhibition</li> </ul>	Laurence Albiges, FR Viktor Grünwald, DE
10'	Individualized therapy in frontline	Laurence Albiges, FR
15'	Second line and beyond in RCC	Stefanie Zschäbitz, DE
20'	Biology and treatment of non-clear RCC	Cristina Suárez, ES
15'	Q&A	All
<b>10:20-10:50</b>	<b>Coffee break</b>	
<b>10:50-12:15</b> <b>85'</b>	<b>SESSION 6</b> <b>Focus on toxicity and duration of therapy</b>	<b>Chairs:</b> <b>Laurence Albiges, FR</b> <b>Bernadett Szabados, UK</b>
15'	Can we stop targeted therapy, immune therapy?	Viktor Grünwald, DE
15'	All you need to know on ADC toxicity management	Ursula Vogl, CH
10'	All you need to know on FGR inhibitor toxicity management	Patrizia Giannatempo, IT
15'	Q&A	All
30'	Participants clinical case discussion (3x10')	Faculty
<b>12:15-12:25</b> <b>10'</b>	<b>Conclusion and farewell</b>	<b>Laurence Albiges, FR</b> <b>Viktor Grünwald, DE</b>
<b>12:25-13:25</b>	<b>Lunch</b>	

**Note:** Each 10-minute slot for clinical case discussion includes a 5' case presentation and a 5' Q&A / discussion